Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jaren Mullen

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Cancer Treatment Reviews|October 7, 2021
Targeting ARID1A mutations in cancerJaren Mullen, Shumei Kato, Jason K Sicklick, et al.
Journal of Medical Case Reports|August 31, 2022
Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case seriesMina Nikanjam, Jaren Mullen, Carol Yacoub, et al.
BMJ Global Health|March 20, 2023
A comprehensive and healthcare equity promoting response by a civil society-public partnership to COVID-19 in Chiapas, MexicoAna Laura Rodríguez, Zeus Aranda, Elvire Brun, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Cancer Treatment Reviews|October 7, 2021
Targeting ARID1A mutations in cancerJaren Mullen, Shumei Kato, Jason K Sicklick, et al.
Journal of Medical Case Reports|August 31, 2022
Combination high-dose interleukin-2 and nivolumab for programmed cell death-1 refractory metastatic melanoma: a case seriesMina Nikanjam, Jaren Mullen, Carol Yacoub, et al.
BMJ Global Health|March 20, 2023
A comprehensive and healthcare equity promoting response by a civil society-public partnership to COVID-19 in Chiapas, MexicoAna Laura Rodríguez, Zeus Aranda, Elvire Brun, et al.
Pageof 1